Bisphosphonates are synthetic analogues of pyrophosphate that inhibit bone resorption by their action on osteoclasts. Bisphosphonates have been extensively used in the elderly with primary and secondary osteoporosis, Paget's disease, and hypercalcemia of malignancy. In recent years, bisphosphonates have been used to treat children acutely for resistant hypercalcemia and chronically for various metabolic bone diseases. The theoretical concerns of possible adverse effects of these drugs on the growing skeleton have not been proven to be true. In the present review, we have critically analyzed the available literature on bisphosphonate therapy in both adult and pediatric clinical trials. Although not yet approved by the FDA for use in children, bisphosphonates, from published experience, demonstrate benefit to the child with no serious adverse effects. Based on the literature analysis the review furnishes detailed recommendations and practical guidelines regarding the use of oral and intravenous bisphosphonates in children. Bisphosphonates might be the first agents to provide the pediatrician with an opportunity to treat mineral and bone disorders of childhood, which until recently did not have satisfactory therapy.
Get full access to this article
View all access options for this article.
References
1.
1. Schibler D, Russell RG, Fleisch H. Inhibition by pyrophosphate and polyphosphate of aortic calcification induced by vitamin D3 in rats. Clin Sci. 1968;35:363-372.
2.
2. Smith R, Russell RGG, Bishop M. Diphosphonates and Paget's disease of bone. Lancet. 1971;1:945-947.
3.
3. Siris ES, Chines AA, Altman RD, et al. Risedronate in the treatment of Paget's disease of bone: an open label, multicenter study. J Bone Miner Res. 1998;13:1032-1038.
4.
4. Thiebaud D,Jaeger P, Gobelet C, et al. A single infusion of the bisphosphonate AlHPrBP (APD) as treatment of Paget's disease of bone. Am J Med. 1988;85:207-212.
5.
5. Ryan PJ, Sherry M, Gibson T, Fogelman I. Treatment of Paget's disease by weekly infusions of 3-aminohydroxypropylidene-l1, 1-bisphosphonate (APD). Br J Rheumatol. 1992;31:97-101.
6.
6. Fenton AJ, Gutteridge DH, Kent GN, et al. Intravenous aminobisphosphonate in Paget's disease: clinical, biochemical, histomorphometric and radiological responses. Clin Endocrinol (Oxj). 1991;34:197-204.
7.
7. Body JJ. Clinical research update: zoledronate. Cancer. 1997;80:1699-1701.
9. Pecherstorfer M, Herrmann Z, Body JJ, et al. Randomized phase II trial comparing different doses of the bisphosphonate ibandronate in the treatment of hypercalcemia of malignancy. JClin Oncol. 1996;14:268-276.
10.
10. Ralston SH, Thiebaud D, Herrmann Z, et al. Dose-response study of ibandronate in the treatment of cancer-associated hypercalcaemia. Br.J Cance7. 1997;75:295-300.
11.
11. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet. 1996;348:1535-1541.
12.
12. Watts NB, Harris ST, Genant HK, et al. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N EnglJ Med. 1990;323:73-79.
13.
13. Liberman UA, Weiss SR, Broll J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. NEnglJMed. 1995;333:1437-1443.
14.
14. Storm T, Thamsborg G, Steiniche T, et al. Effect of intermittent cyclical etidronate therapy on bone mass and fractu-re rate in women with postmenopausal osteoporosis. N EnglJ Med. 1990;322:1265-1271.
15.
15. Chesnut CH III, McClung MR, Ensrud KE, et al. Alendronate treatment of the postmenopausal osteoporotic woman: effect of multiple dosages on bone mass and bone remodeling. Am J Med. 1995;99:144-152.
16.
16. Eastell R. Treatment of postmenopausal osteoporosis. N Engl J Med. 1998;338:736-746.
17.
17. Heaney RP, Yates AJ, Santora AC II. Bisphosphonate effects and the bone remodeling transient. J Bone Miner Res. 1997;12:1143-1151.
18.
18. Eyre DR. Biochemical markers of bone turnover. In: Favus MJ, ed. Primer on the Metabolic BoneDiseases and Disorders of Mineral Metabolism. 3rd ed.Philadelphia: Lippincott-Raven; 1996:114-119.
19.
19. Garnero P, Shih WJ, Gineyts E, et al. Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab. 1994;79:1693-1700.
20.
20. van Beek E, Hoekstra M, van de Ruit M, et al. Structural requirements for bisphosphonates actions in vitro. J Bone Miner Res. 1994;9:1875-1882.
21.
21. Rodan GA, Fleisch HA. Bisphosphonates: mechanisms of action. J Clin Invest. 1996;97:2692-2696.
22.
22. Rowe DJ, Hausmann E. The effects of calcitonin and colchicine on the cellular response to diphosphonate. Br J Exp Pathol. 1980;61:303-309.
23.
23. Nishikawa M, Yamamoto M,Murakami T, et al. A third-generation bisphosphonate, YM175, inhibits osteoclast formation in murine cocultures by inhibiting proliferation of precursor cells via supporting cell-dependent mechanisms. J Bone Miner Res. 1998; 13:986-995.
24.
24. Hughes DE, Wright KR, Uy HL, et al. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Miner Res. 1995; 10: 1478-1487.
25.
25. Selander KS, Monkkonen J, Karhukorpi EK, et al. Characteristics of clodronate-induced apoptosis in osteoclasts and macrophages. MolPharmacol. 1996;50:1127-1138.
26.
26. Flanagan AM, Chambers TJ. Inhibition of bone resorption by bisphosphonates: interactions between bisphosphonates, osteoclasts, and bone. Calcif Tissue Int. 1991;49:407-415.
27.
27. Carano A, Teitelbaum SL, Konsek JD, et al. Bisphosphonates directly inhibit the bone resorption activity of isolated avian osteoclasts in vitro. J Clin Invest. 1990;85:456-461.
28.
28. Sato M, Grasser W, Endo N, et al. Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure. J Clin Invest. 1991;88:2095-2105.
29.
29. Zimolo Z, Wesolowski G, Rodan GA. Acid extrusion is induced by osteoclast attachment to bone. Inhibition by alendronate and calcitonin. J Clin Invest. 1995;96:2277-2283.
30.
30. Vitte C, Fleisch H, Guenther HL. Bisphosphonates induce osteoblasts to secrete an inhibitor of osteoclast-mediated resorption. Endocrinology. 1996;137:2324-2333.
31.
31. Sahni M, Guenther HL, Fleisch H, et al. Bisphosphonates act on rat bone resorption through the mediation of osteoblasts. J Clin Invest. 1993;91:2004-2011.
32.
32. Kleerekoper M, Avioli LV. Evaluation and treatment of postmenopausal osteoporosis. In: Favus MJ, ed. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. 3rd ed.Philadelphia: Lippincott-Raven; 1996:264-271.
33.
33. Bell NH, Johnson RH. Bisphosphonates in the treatment of osteoporosis. Endocrine. 1997;6:203-206.
34.
34. Horowitz E, Miller JL, Rose LI. Etidronate for hypercalcemia of malignancy and osteoporosis. Am Fam Physician. 1991;43:2155-2159.
35.
35. Machado CE, Flombaum CD. Safety of pamidronate in patients with renal failure and hypercalcemia. Clin Nephrol. 1996;45:175-179.
36.
36. Yap AS, Hockings GI, Fleming SJ, Khafagi FA. Use of aminohydroxypropylidene bisphosphonate (AHPrBP, “APD”) for the treatment of hypercalcemia in patients with renal impairment. Clin Nephrol. 1990;34: 225-229.
37.
37. Davenport A, Goel S, Mackenzie JC. Treatment of hypercalcaemia with pamidronate in patients with end stage renal failure. Scand J Urol Nephrol. 1993;27:447-451.
38.
38. Rossini M, Gatti D, Zamberlan N, et al. Long-term effects of a treatment course with oral alendronate of postmenopausal osteoporosis. J Bone Miner Res. 1994;9:1833-1837.
40. Adachi JD, Bensen WG, Brown J, et al. Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. N Engl J Med. 1997;337:382-387.
41.
41. Saag KG, Emkey R, Schnitzer TJ, et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. NEnglJMed. 1998;339:292-299.
42.
42. Lipton A. Bisphosphonates and breast carcinoma. Cancer. 1997;80:1668-1673.
43.
43. Kanis JA, Powles T, Paterson AH, et al. Clodronate decreases the frequency of skeletal metastases in women with breast cancer. Bone. 1996;19:663-667.
44.
44. Conte PF, Latreille J, Mauriac L, et al. Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomized controlled trial. The Aredia Multinational Cooperative Group. J Clin Oncol. 1996;14:2552-2559.
45.
45. Elomaa I, Blomqvist C, Grohn P, et al. Long-term controlled trial with diphosphonate in patients with osteolytic bone metastases. Lancet. 1983;1:146-149.
46.
46. Sasaki A, Boyce BF, Story B, et al. Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice. Cancer les. 1995;55:3551-3557.
47.
47. van der Pluijm G, Vloedgraven H, van Beek E, et al. Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro. J Clin Invest. 1996;98:698-705.
48.
48. Gray J, Shaw T. Use of bisphosphonates in preoperative treatment of patients with hyperparathyroidism. Surgery. 1993;113:594-594.
49.
49. Tisell LE, Hedback G,Jansson S, et al. Management of hyperparathyroid patients with grave hypercalcemia. World J Surg. 1991;15:730-737.
50.
50. Singer FR, Minoofar PN. Bisphosphonates in the treatment of disorders of mineral metabolism. Adv Endocrinol Metab. 1995;6:259-288.
51.
51. Hene RJ, Visser WJ, Duursma SA, et al. No effect of APD (amino hydroxypropylidene bisphosphonate) on hypercalcemia in patients with renal osteodystrophy. Bone. 1990;11:15-20.
52.
52. Nussbaum SR. Pathophysiology and management of severe hypercalcemia. Endocrinol Metab Clin North Am. 1993;22:343-362.
53.
53. Gurney H, Grill V, Martin TJ. Parathyroid hormone related protein and response to pamidronate in tumor-induced hypercalcemia. Lancet. 1993;341:1611-1613.
54.
54. Lahtinen R, Laakso M, Palva I, et al. Randomized, placebo-controlled multicentre trial of clodronate in multiple myeloma. Finnish Leukaemia Group. Lancet. 1992;340:1049-1052.
55.
55. Berenson JR, Lichtenstein A, Porter L, et al. Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group. J Clin Oncol. 1998;16:593-602.
56.
56. Berenson JR, Lichtenstein A, Porter L, et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. N Engl J Med. 1996;334:488-493.
57.
57. Shipman CM, Rogers MJ, Apperley JF, et al. Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti-tumour activity. Br J Haematol. 1997;98:665-672.
58.
58. Stover SL, Hahn HR, Miller JM III. Disodium etidronate in the prevention of heterotopic ossification following spinal cord injury. Paraplegia. 1976; 14:146-156.
59.
59. Oliveri MB, Mautalen C, Mega M, Rossi E. Congenital erythropoietic porphyria: skeletal manifestations and effect of pamidronate treatment. Bone. 1994;15:101-104.
60.
60. Weinstein RS. Long-term aminobisphosphonate treatment of fibrous dysplasia: spectacular increase in bone density. J Bone Miner Res. 1997; 12:1314-1315.
61.
61. Pfeilschifter J, Ziegler R. Wirkung von pamidronat auf beschwerdebild und knochenstoffwechsel bei fibroser dysplasie und McCune-Albright-Syndrom. Med Klin. 1998;93:352-359.
62.
62. Liens D, Delmas PD, Meunier PJ. Long-term effects of intravenous pamidronate in fibrous dysplasia of bone. Lancet. 1994;343:953-954.
63.
63. Brumsen C, Hamdy NA, Papapoulos SE. Long-term effects of bisphosphonates on the growing skeleton. Studies of young patients with severe osteoporosis. Medicine (Baltimore). 1997; 76:266-283.
64.
64. Hoekman K, Papapoulos SE, Peters AC, Bijvoet OL. Characteristics and bisphosphonate treatment of a patient with juvenile osteoporosis. J Clin Endocrinol Metab. 1985;61:952-956.
65.
65. Shaw NJ, White CP, Fraser WD, Rosenbloom L. Osteopenia in cerebral palsy. Arch Dis Child. 1994;71:235-238.
66.
66. Lepore L, Pennesi M, Barbi E, Pozzi R. Treatment and prevention of osteoporosis in juvenile chronic arthritis with disodium clodronate. Clin Exp Rheumatol. 1991;9(Suppl 6):33-35.
67.
67. Glorieux FH, Bishop NJ, Plotkin H, et al. Cyclic administration of pamindronate in children with severe osteogenesis imperfecta. N Engl j Med. 1998;339:947-952.
68.
68. Glorieux FH, Travers R, Chabot G, Lanoue G. Bone histomorphometric analysis in osteogenesis imperfecta. J BoneMinerRes. 1994;9(Suppl 1):A504-A504.
69.
69. Devogelaer JP, Malghem J, Maldague B, Nagant de Deuxchaisnes C. Radiological manifestations of bisphosphonate treatment with APD in a child suffering from osteogenesis imperfecta. Skeletal Radiol. 1987;16:360-363.
70.
70. Huaux JP, Lokietek W. Is APD a promising drug in the treatment of severe osteogenesis imperfecta?J Pediatr Orthop. 1988;8:71-72.
71.
71. Bembi B, Parma A, Bottega M, et al. Intravenous pamidronate treatment in osteogenesis imperfecta. J Pediatr.1997;131:622-625.
72.
72. Fujiwara I, Ogawa E, Igarashi Y, et al. Intravenous pamidronate treatment in osteogenesis imperfecta. Eur J Pediatr. 1998;157:261-262.
73.
73. Cassinelli HR, Mautalen CA, Heinrich Jj, et al. Familial idiopathic hyperphosphatasia (FIH): response to longterm treatment with pamidronate (APD). Bone Miner. 1992;19:175-184.
74.
74. Attard TM, Dhawan A, Kaufman SS, et al. Use of disodium pamidronate in children with hypercalcemia awaiting liver transplantation. Pediatr Transplantation. 1998;2:157-159.
75.
75. Profumo RJ, Reese JC, Foy TM, et al. Severe immobilization-induced hypercalcemia in a child after liver transplantation successfully treated with pamidronate. Transplantation. 1994; 57:301-303.
76.
76. Rawlinson PS, Green RH, Coggins AM, et al. Malignant osteopetrosis: hypercalcaemia after bone marrow transplantation. Arch Dis Child. 1991; 66:638-639.
77.
77. Yamaguchi K, Grant J, Noblejamieson G, et al. Hypercalcaemia in primary oxalosis: role of increased bone resorption and effects of treatment with pamidronate. Bone. 1995;16:61-67.
78.
78. Boudailliez BR, Pautard BJ, Sebert JL, et al. Leukaemia-associated hypercalcaemia in a 10-year-old boy: effectiveness of aminohydroxypropylidene bisphosphonate. Pediatr Nephrol. 1990; 4:510-511.
79.
79. Lteif AN, Zimmerman D. Bisphosphonates for treatment of childhood hypercalcemia. Pediatrics. 1998;102:990-993.
80.
80. Varache N, Audran M, Clochon P, et al. Aminohydroxypropylidene bisphosphonate (AHPrBP) treatment of severe immobilization hypercalcaemia in a young patient. Clin Rheumatol. 1991;10:328-332.
81.
81. Williams CJ, Smith RA, Ball RJ, Wilkinson H. Hypercalcaemia in osteogenesis imperfecta treated with pamidronate. Arch Dis Child. 1997;76: 169-170.
82.
82. Sellers E, Sharma A, Rodd C. The use of pamidronate in three children with renal disease. Pediatr Nephrol. 1998; 12:778-781.
83.
83. Meradji M, de Villeneuve VH, Huber J, et al. Idiopathic infantile arterial calcification in siblings: radiologic diagnosis and successful treatment. J Pediatr.1978;92:401-405.
84.
84. Vera J, Lucaya J, Garcia Conesaj A, et al. Idiopathic infantile arterial calcification: unusual features. Pediatr Radiol. 1990;20:585-587.
85.
85. Thiaville A, Smets A, Clercx A, Perlmutter N. Idiopathic infantile arterial calcification: a surviving patient with renal artery stenosis. Pediatr Radiol. 1994;24:506-508.
86.
86. Bassett CA, Donath A, Macagno F, et al. Diphosphonates in the treatment of myositis ossificans. Lancet. 1969; 2:845-845.
87.
87. Rogers JG, Dorst JP, Geho WB. Use and complications of high-dose disodium etidronate therapy in fibrodysplasia ossificans progressiva. J Pediatr.1977;91:1011-1014.
88.
88. Samuel R, Katz K, Papapoulos SE, et al. Aminohydroxy propylidene bisphosphonate (APD) treatment improves the clinical skeletal manifestations of Gaucher's disease. Pediatrics. 1994;94:385-389.
89.
89. Bembi B, Agosti E, Boehm P, et al. Aminohydroxypropylidene-bisphosphonate in the treatment of bone lesions in a case of Gaucher's disease type 3. Acta Paediatr. 1994;83:122-124.
90.
90. de Groen PC, Lubbe DF, Hirsch LJ, et al. Esophagitis associated with the use of alendronate. N Engl J Med. 1996; 335:1016-1021.
91.
91. Landman JO, Hamdy NA, Pauwels EK, Papapoulos SE. Skeletal metabolism in patients with osteoporosis after discontinuation of long-term treatment with oral pamidronate. J Clin Endocrinol Metab. 1995;80:3465-3468.
92.
92. van Persijn van Meerten EL, Kroon HM, Papapoulos SE. Epiand metaphyseal changes in children caused by administration of bisphosphonates. Radiology. 1992;184:249-254.
93.
93. Belch AR, Bergsagel DE, Wilson K, et al. Effect of daily etidronate on the osteolysis of multiple myeloma. J Clin Oncol. 1991;9:1397-1402.
